

## Indicators of Co-occurrence of Mood Disorder with Chronic Medical Conditions: Evidence from an Administrative Claims Data Analysis

Karishma Chhabria<sup>1,2</sup> Ph.D. MPH <https://orcid.org/0000-0001-5028-023X>, Trudy Millard Krause<sup>1</sup> DrPH <https://orcid.org/0000-0002-6740-4734>, Randa Hamden<sup>1</sup> Ph.D. <https://orcid.org/0000-0002-4335-7152>, Mbemba Jabbi<sup>3,4,5</sup>, Ph.D., MSc <https://orcid.org/0000-0001-5263-5321>

<sup>1</sup>Division of Management Policy and Community Health, Center for Healthcare Data Research, UTHealth School of Public Health

<sup>2</sup>Department of Public Health, Usha Kundu, MD College of Health, University of West Florida

<sup>3</sup>Department of Psychiatry and Behavioral Sciences, Dell Medical School, the University of Texas at Austin.

<sup>4</sup>Institute for Neuroscience & Center for Learning and Memory, the University of Texas at Austin.

<sup>5</sup>Mulva Clinics for the Neurosciences, Dell Medical School

### Corresponding author:

Mbemba Jabbi, Ph.D., MSc.  
Department of Psychiatry and Behavioral Sciences  
University of Texas at Austin Dell Medical School  
Health Discovery Building, HDB 4.210  
1701 Trinity Street, Austin, Texas 78712  
Email: [mbemba.jabbi@austin.utexas.edu](mailto:mbemba.jabbi@austin.utexas.edu)

*Main text word count: 3044 words*

*Number of tables/figures: 3*

*Number of Supplemental Files: 2*

Conflicts of Interest and Source of Funding: None to disclose.

## ABSTRACT

**Objective** Mood disorder (including major depression and bipolar disorder) prevalence is over 10% and accounts for a significant share of global disease burden. Mental and physical illness are related, however, the association between mood disorders and acute/chronic disease subclasses remains poorly understood.

**Methods** This observational cross-sectional study used administrative claims data from 6,709,258 adult enrollees with a full-year enrollment in the 2018 OPTUM Clinformatics® database. Data of enrollees with/without diagnoses of a mood disorder co-occurring with chronic comorbid conditions (defined by the Elixhauser Comorbidity Index) using the International Classification of Diseases (ICD-10) were analyzed by accounting for age, race, and ethnicity.

**Results** Overall, the sample was predominantly non-Hispanic Caucasians (64.56%), with 48.59% females and a mean age of 43.54 years $\pm$ 12.46 years. The prevalence of mood disorders was 3.71% (248,890), of which 0.61% (n=40,616) had bipolar disorders and 3.10% (n=208,274) had Major Depressive Disorder (MDD). Logistic regression odds ratios revealed a strong association between mood disorder diagnoses and peptic ulcers (2.11; CI=2.01-2.21), weight loss (2.53; CI, 2.46-2.61), renal failure (2.37, CI = 2.31-2.42), peripheral vascular disease (2.24; CI=2.19-2.30), and pulmonary circulation disorder (1.77; CI=1.70-1.84).

**Conclusions** Overall, mood disorders were associated with vascular and cardiac chronic medical conditions, suggesting a possible pathophysiological link between these conditions. The results highlight the importance of understanding the prevalence of co-occurring mood and medical conditions and may inform novel biological diagnostics and future identification of mechanisms for multimorbidity.

**Keywords:** Bipolar, major depressive disorder, mood disorder, administrative claims

## INTRODUCTION

Mood disorders have a lifetime prevalence of over 10% worldwide (Murray et al., 2012; Collins et al., 2011; Kessler et al., 2007; Kessler et al., 2008; Plana-Ripoll et al., 2019). Mood disorders present a substantial share of the global disease burden as measured with disability-adjusted life years (DALYs) (Saloni Dattani, 2021; Whiteford et al., 2016). Globally, mood disorders affect approximately 310 million people, of which 264 million were documented to have a major depressive disorder (MDD) and 46 million had bipolar disorders (Dattani et al. 2023). The negative impact of mood disorders and co-occurring mental disorders on global disease burden and DALYs, a metric that considers both disorder-associated mortality and years lived with disability. Mood disorders also accounts for many premature mortalities, including close to a million suicides annually across the world (Evans et al., 2005; Ferrari et al., 2013; Momen et al., 2020; Weye et al., 2020). The hallmark of mood disorders (including major depressive disorder (MDD) and bipolar disorders) is debilitating depressive episodes that can co-occur with medical diseases like cardiovascular disease, autoimmune disease, and metabolic diseases such as diabetes (Momen et al., 2020). Although evidence suggests a strong association between mood disorders and co-occurring acute/chronic medical disease diagnoses (Evans et al., 2005; Ormel et al., 2007; Weye et al., 2020), the specific nature of the associations between mood disorders and subtypes of acute/chronic conditions remains understudied.

Indeed, several studies have separately assessed the association between MDD or bipolar disorder and other acute/chronic medical conditions (see comprehensive review by Evans et al.) (Evans et al., 2005; Machado et al., 2018). In a systematic review and meta-analysis of 40 articles, it was found that the risk for a diagnosis of depression was twice more likely for people with multimorbidity, the presence of two or more chronic conditions, in comparison to people without multimorbidity (Read et al. 2017). Furthermore, this observed risk for a depression diagnosis was three times greater for people with multimorbidity compared to those without any chronic physical condition (Read et al. 2017). However,

evidence of an integrative cross-association between MDD and bipolar disorder with acute/chronic medical conditions is sparse.

Given that the diagnoses of MDD and bipolar disorder are often interrelated such that individuals initially diagnosed with MDD can subsequently have their diagnosis changed/rectified to be either bipolar disorder Type II or bipolar disorder type I, examining the association between mood disorders (which includes MDD and bipolar) and other conditions is therefore essential for the comprehensive understanding of the biological complexities underlying comorbid conditions. Depressive symptoms account for a significant disease burden for both MDD and bipolar disorders, and there is a clear need for a broader mood disorder-focused approach to understanding the pathological complexities of these prevalent conditions at the population level. Here, we studied the association of mood disorders with acute/chronic medical condition subtypes in a population of almost 7 million U.S. private insurance policyholders. Our study used administrative claims data to investigate mood disorders' (including separate analysis for MDD and bipolar disorder) differential association and co-existence with acute/chronic disease comorbidities as defined by the Elixhauser's comorbidity index (Elixhauser et al., 1998).

## **METHODS**

### **Study Design and Population**

We performed a retrospective observational study using OPTUM Clinformatics® Data Mart (CDM) to capture one year of claims data in 2018 (from January 1<sup>st</sup> to December 31<sup>st</sup>). Our outcome of interest was defined as those with or without MDD, those with or without bipolar disorder, and a combination of MDD and bipolar disorder (referred to here as mood disorder). We compared our outcomes to those with and without chronic medical comorbidities as defined by Elixhauser's comorbidity index (Elixhauser et al., 1998). The study sample included 6,709,258 adult enrollees between the ages of 21-64 years who were continuously enrolled for all 12 months of 2018 in OPTUM CDM.

OPTUM Clinformatics® Data Mart (CDM) is a statistically de-identified, HIPAA-complaint, closed system of insurance administrative claims, including patient enrollment; physician, facility, and pharmacy claims; and lab results from the largest health insurer in the U.S. Administrative claims data are collected for billing purposes hence data reported here are indicative of healthcare encounters with a recorded International Classification of Disease 10<sup>th</sup> Edition (ICD-10) diagnosis codes. This database was accessed through The University of Texas Health Sciences Center Houston (UTHSC-H) School of Public Health Center for Health Care Data (CHCD). The UTHSC-H institutional review board approved the study. Since this study utilized de-identified administrative claims data via secondary data analysis, informed consent was not obtained. The data is available directly through OPTUM Clinformatics® Data Mart

## **Measurements**

A mood disorder diagnosis claim was assessed using ICD-10 diagnostic codes that capture the presence of bipolar disorder (includes bipolar I and II disorder), or MDD, during either inpatient or outpatient care encounters in 2018 (Appendix 2). Insurance claims data are collected for billing purposes; hence, claims evaluated in this study were recorded healthcare encounters such as diagnostic records from a psychiatrist or psychologist. We evaluated the frequency of healthcare encounters for MDD and bipolar disorder in the claims. Enrollees included in the bipolar disorder group were those with a definitive bipolar I or bipolar II disorder diagnosis (obtained from the claims data through healthcare encounters) in the study period. Enrollees that were categorized as having MDD were those who had a definitive diagnosis of MDD, regardless of a co-existing bipolar disorder diagnosis, with the exception that the frequency of MDD-related healthcare encounters would be greater than bipolar disorder. There were 2,594 enrollees with an equal frequency of claims (i.e., an equal number of healthcare encounters) for a diagnosis of MDD and bipolar disorder. Because these enrollees could not be definitively assigned to either group, they were excluded from our analysis.

As defined by the Elixhauser Comorbidity Index, acute/chronic comorbidities include 31 indicators that reflect acute/chronic medical conditions with significant short or long-term consequences on physical health (Elixhauser et al., 1998; Kim et al., 2018; Menendez et al., 2015; van Walraven et al., 2009). We assessed 24 indicators: blood loss anemia, cardiac arrhythmia, chronic pulmonary disease, coagulopathy, congestive heart failure, deficiency anemia, diabetes complicated, diabetes uncomplicated, fluid conditions, HIV/AIDS, hypertension, hypothyroidism, liver disease, lymphoma, metastatic cancer, obesity, peptic ulcers, peripheral vascular disorder, pulmonary circulation disorder, rheumatoid arthritis, renal failure, tumor without metastasis, valvular disease, and weight loss. We combined hypertension complicated and uncomplicated into a single indicator called hypertension. To account for additional factors that could influence the risk of study outcomes, we assessed demographics such as age, sex, and race/ethnicity as recorded in the patient's enrollment file and included these variables in the analysis.

Adults with neurological or another primary diagnosis of a psychiatric condition, namely paralysis, neurological conditions, drug/alcohol use disorder diagnosis, and paralysis were excluded. Adults institutionalized in long-term care facilities were also excluded from the study due to the neurobiological cross-link between these indicators and study outcomes. (Appendix 1) (Devanand et al., 2022) (Collins et al., 2011)..

## **Statistical Analysis**

We performed descriptive statistics by first evaluating means, standard deviations, and prevalence of each co-existing acute/chronic comorbid medical condition across mood disorder subtypes. Unadjusted and adjusted odds ratios (OR) and confidence intervals (CI) were then calculated using binary variables for the presence or absence of exposure (acute and chronic medical conditions) and outcome diagnosis (pooled mood disorders, bipolar disorders, and MDD separately). Multivariable logistic regression models were used to evaluate the association of 1) bipolar disorder, 2) MDD, and 3) mood disorders based on comorbid conditions while accounting for age, sex, and race/ethnicity. Comorbid medical

conditions that showed the top 5 highest prevalence ratios, i.e., a ratio calculated using prevalence rates from the overall population and mood disorder subtype, were included in the logistic models.

To assess the effects of age, we categorized age into four groups: 21-30 years, 31-40 years, 41-50 years, and 41-64 years for descriptive statistics but used it as a continuous variable in the logistic regression. We also included an interaction term between sex and age in our logistic models. Three separate models were run for each outcome: bipolar disorder, MDD, and mood disorders. The goodness of fit statistics and model convergence status were evaluated to assess model significance. Statistical significance was set at 0.05 a priori, and statistical analysis was performed using SAS, version 9.4 (SAS Institute Inc).

## **RESULTS**

From the 2018 Optum enrollment records, 6,709,258 enrollees met our inclusion criteria. The final sample of included enrollees were majority non-Hispanic Caucasians (64.56%), with a mean age of 43.54 (SD = 12.46) years. Table 1 presents the demographics and ethnicity of the included sample, of which 3.71% had a mood disorder diagnoses (n = 248,890), with the mood disorder sample comprising 0.61% bipolar disorder (n = 40,616) and 3.10% MDD (n = 208,274) of the total sample. Table 2 presents descriptive statistics of each chronic condition by study outcomes. We found that most of the included individuals in the non-mood disorder sample had no comorbid conditions (63.80%), while 36.20% had one or more of the identified comorbid medical conditions. Further, 64.56% of patients with a mood disorder had at least one comorbid medical condition. The most prevalent medical condition was hypertension, which affected 1,214,122 people (i.e., 18.97% of the non-mood disorder sample) (Table 2). Hypertension was also present in 34.46% of the mood disorder sample, of which 35.02% also had bipolar disorder, while 34.35% of the MDD sample had hypertension (Table 2).

### **Prevalence Ratio Analyses**

Using the prevalence ratio calculation, we found the top 5 most prevalent comorbid medical conditions for bipolar disorders included weight loss (3.49), renal failure (3.30), fluid conditions (3.11), and peptic ulcers (3.05). Similar prevalence ratio calculations revealed that the top 5 most prevalent comorbid medical conditions for MDD included weight loss (3.04), chronic pulmonary circulation disorder (2.87), peripheral vascular disorder (2.85), and rheumatoid arthritis (2.73).

Based on prevalence ratio calculation, the top 5 prevalent comorbid medical conditions we found to be associated with mood disorders included weight loss (3.12), peptic ulcers (2.88), pulmonary circulation disorder (2.85), peripheral vascular disorder (2.84) and renal failure (2.81).

### **Multivariable Logistic Regression Analyses**

Multivariate logistic regression met the criteria for convergence and goodness of fit for each of the models: bipolar disorders (percent concordant = 56.00), MDD (percent concordant = 63.70), and pooled mood disorders group (percent concordant = 63.80).

As shown in Table 3, the adjusted logistic regression model revealed a significant association between bipolar disorder and the top 5 conditions, including peptic ulcers (OR, 1.61; 95% CI, 1.45-1.81), weight loss (OR, 2.02, 95% CI, 1.89-2.15), renal failure (OR, 2.10, 95% CI = 1.99 – 2.20), fluid conditions (OR, 1.87; 95% CI, 1.79 – 1.95), and chronic pulmonary disease (OR, 2.70; 95% CI, 2.63-2.77). The model further revealed that being Caucasian, of advanced age (OR=1.00, 95% CI = 1.00 – 1.00), and being female (OR = 2.05, 95% CI = 2.01- 2.10) were associated with bipolar disorders diagnosis. The interaction term between age and sex is also significantly associated with bipolar disorders diagnosis (OR=2.05, 95% CI = 2.01 – 2.10, p-value = 0.001) (Table 3).

As shown in Table 3, the adjusted logistic model revealed an association of MDD with the top 5 prevalence ratio conditions, including peptic ulcers (OR, 2.05; 95% CI, 1.95-2.17), weight loss (OR, 2.46; 95% CI, 2.38-2.54), peripheral vascular disease (OR, 2.44; 95% CI, 2.38-2.51), pulmonary circulation disorder (OR, 1.91; 95% CI, 1.83-2.00), and rheumatoid arthritis (OR, 2.06; 95% CI, 2.01-2.10). Further, the adjusted logistic regression model showed that being Caucasian, older age, and female increased the



likelihood of having MDD, while sex interacted with age such that older female adults had a higher likelihood of having MDD (OR, 2.38; 95% CI, 2.36-2.40).

The adjusted logistic regression model shows the top 5 prevalence ratio comorbid medical conditions for mood disorders to include peptic ulcers (OR=2.11, 95% CI = 2.01 – 2.21), weight loss (OR=2.53, 95% CI = 2.46 – 2.61), renal failure (OR=2.37, 95% CI = 2.31 – 2.42), pulmonary circulation disorder (OR=1.77, 95% CI = 1.70 – 1.84) and peripheral vascular disease (OR=2.24, 95% CI = 2.19 – 2.30) (Table 5). Furthermore, Caucasians were found to have the highest likelihood of a mood disorder diagnosis compared to other races ( $p < 0.001$ ). Females were 2.4 times more likely to have a mood disorder diagnosis (OR=2.43, 95% CI = 2.41 – 2.46), and the observed sex effect interacted with age in that older females were more likely to have a mood disorder diagnosis (OR=2.42, 95% CI = 2.40 – 2.44).

## DISCUSSION

Mood disorders affect over ten percent of the population over the lifespan and frequently co-occur with comorbid medical conditions (Dalby et al. 2022). In this observational study, we used insurance claims data to understand the associations (or co-occurrence) between mood disorders and chronic comorbid conditions using records of healthcare encounters via healthcare insurance claims. Although our results are strictly observational and therefore can not address causality based on the analysis and overall approach of our study, our results did reveal strong associations between mood disorders with 1) peptic ulcers, 2) weight loss, 3) renal failure, 4) pulmonary circulation disorder, and 5) peripheral vascular disorder. These vascular and cardiac disease associations with mood disorder diagnoses align with earlier work (Evans et al., 2005; Momen et al., 2020; Momen et al., 2022). Bipolar disorder diagnosis was associated with 1) peptic ulcers, 2) weight loss, 3) renal failure, 4) fluid conditions, and 5) chronic pulmonary disease. MDD, on the other hand, was associated with 1) peptic ulcers, 2) weight loss, 3) peripheral vascular disease, 4) pulmonary circulation disorder, and 5) rheumatoid arthritis (Momen et al., 2020; Momen et al., 2022). These findings align with previous results showing strong associations between mood disorders and ulcers, weight loss, cardiovascular diseases (Evans et al., 2005; Momen et

al., 2022), and pulmonary diseases (Panagioti et al. 2014). For instance, Panagioti et al. showed that over one-third of individuals with chronic obstructive pulmonary disease suffer comorbid mood and anxiety disorders (Panagioti et al. 2014). In another independent report, the number of comorbidities between chronic diseases and mental disorders has been shown to influence overall treatment outcomes (Garvey & Criner 2018).

In our large-scale study sample, we found a fivefold higher prevalence of MDD in the overall sample than in bipolar disorder. Within the pooled mood disorders sample, the association between weight loss was the highest observed somatic disease comorbidity, in line with weight instability being a core somatic symptom of mood disorders. Although MDD is more prevalent than bipolar disorder, bipolar disorder is documented to be more heritable (i.e., bipolar disorder has a higher familial diagnostic occurrence than MDD) (McIntyre et al., 2020; Mendlewicz, 2009; Otte et al., 2016). Our findings of convergent associations between comorbid medical conditions and both bipolar disorders and MDD (i.e., mood disorders) suggest possible comorbidity overlaps across mood disorders and sub-classes of acute/chronic diseases when these medical conditions are classified according to biological/organ-specific dysfunctions (see Tylee D.S. et al. 2022 as an example) (Tylee et al., 2022).

There likely are many possible causal or biological mechanisms driving the observed comorbidities. For instance, environmental pathogens, such as infective agents and socially adverse as well as naturally adverse experiences, can cumulatively cause excessive inflammatory responses that can lead to or exacerbate various chronic and mental diseases (Baltrusch et al. 1991; von Kanel 2012; Stuller et al. 2012; Nikiphorou et al. 2019; Jackson and Jabbi, 2022; Brewerton 2022). Of note, four of the top 5 most likely comorbid medical conditions were the same for bipolar disorder and MDD. Such overlapping associations may echo shared mood disorders etiology in that psychological and environmentally adverse and stressful experiences can trigger emergent mood disorders and cardiovascular and other somatic conditions (Jabbi and Nemeroff, 2019; Baltrusch et al. 1991; von Kanel, 2012; Stuller et al. 2012; Nikiphorou et al. 2019; Jackson and Jabbi, 2022; Brewerton, 2022). In addition, this idea aligns with a recent study showing that a history of mental stress, with and without conventional stress, was associated

with a significantly increased risk for myocardial ischemia with cardiovascular events (Vaccarino et al., 2021).

Together, our findings of comorbid circulatory and cardiovascular disease with mood disorders, in addition to peptic ulcers, weight loss, and renal failure, may have implications for a better understanding of disease outcomes in light of evidence showing increased mortality in depression when co-occurring with cardiovascular and other diseases (Frasure-Smith et al., 1995).

For instance, one hypothesis states that a bidirectional link exists between mood disorders and acute/chronic comorbid conditions (Evans et al., 2005). An alternative hypothesis suggests that mood disorders can affect the course of medical diseases like ischemic heart disease (Ferrari et al., 2013; Frasure-Smith et al., 1995; Headrick et al., 2017) by increasing overall disease burden and negative prognostic and severe disease outcome over time (Frasure-Smith et al., 1995; Manning, 2005; McGuire et al., 2002), including increasing the risk for mortality (Insel and Charney, 2003; Struble et al., 2014) and suicide (Sanna et al., 2014). In line with these models, we found a robust association between mood disorders and gastrointestinal (peptic ulcers), metabolic (weight loss), and acute and chronic circulatory/renal and cardiovascular diseases in a large adult sample of over 6.7 million individuals. These findings indicate a possible additive contribution of mood disorders and acute/chronic medical comorbidities. However, how the observed comorbidities emerge, what their combined disease burden is (Ferrari et al., 2013), and what cumulative impact these measures can have on overall morbidity and mortality indicators, including suicide rates over time, needs to be addressed with future longitudinal studies (Ferrari et al., 2013; McIntyre et al., 2020).

## **Limitations**

This study needs to be interpreted in light of its limitations. *First*, our study examined a one-year window of private insurance claims from January 2018 to December 2018. This focus on 1-year data limits the generalizability of our findings over longer durations. Using a private insurance dataset also limits the

generalizability of our results across populations without private insurance, such as Medicaid and the uninsured.

Furthermore, focusing on active diagnoses without accounting for symptom history, including mood episodic history and remission status, limits the study's ability to shed light on the longer-term implications of the observed comorbidities. However, the use of administrative claims data resulting from healthcare encounters highlights the definitive diagnosis of these conditions as opposed to patient-reported outcomes, which may be subject to bias. Here, we focused only on adults aged 21-64, excluding children, adolescents, post-adolescents, and individuals 65 and older. This selective age window limits the interpretation of our findings beyond the studied age range. *Second*, disease comorbidities can have complex and varying etiological and biological relationships. This complexity implies that more data on the possible biological and etiological correlates of such comorbidities, coupled with data on the time-relevant relationships between the comorbid disorders in terms of what diagnostic subclass emerges first, are needed to better understand the mechanistic aspects of our observed comorbidities. Moreover, our work strictly addresses associations and not causations. However, future studies of the causal relationships between our observed associations using time series of diagnostic data would shed more light on the directional influences of our observed associations. *Third*, we excluded all mental illness and neurological/neuropsychiatric comorbidities given the proximate cross-link between these conditions and mood disorders with brain systems and endpoint behavioral symptoms. While this is necessary, it limits the possibility of assessing if comorbidities between mood disorders and other neuropsychiatric conditions could moderate further prevalence of comorbid mood disorders with mental and medical conditions. Fourth, an individual could be diagnosed with MDD and later develop bipolar disorder. As is commonly known, a one-time diagnostic healthcare record for MDD and a follow-up diagnosis of bipolar disorder after the first onset of mania cannot be identified and excluded in this cohort due to the nature of the claims. However, only the most recent mood disorder diagnosis within the studied period was included. We have additionally integrated both MDD and bipolar disorder into a mood disorder diagnostic group, an approach we adopted to minimize this limitation given the close diagnostic

relationship between the two conditions. *Finally*, we think that leading models positing that mood disorders and medical conditions are bi-directionally associated or that mood disorders can negatively impact medical disease prognoses and outcomes are more complementary than mutually exclusive. Therefore, our study captures associations between the diagnostic presence of comorbid medical conditions and mood disorders in a large sample of over 6.7 million U.S. adults. It cannot assess whether the mood disorder preceded the medical disease onsets and whether the disease course of the medical conditions was affected by the presence of mood disorders. By including 6.7 million individuals in our study and identifying bodily systems-related comorbidities with mood disorder in one year capture using the Elixhauser Comorbidity Index, our observations of mood disorder-medical comorbidities provide further biological insights into the possible pathophysiological underpinnings of complex comorbidities.

## **Conclusion**

This diagnostic association study used the Optum private insurance claims data to assess the association between mood disorders and medical conditions organized in comorbid medical conditions of organ systems. We included over 6.7 million insured individuals using the Elixhauser Comorbidity Index. Although the Elixhauser comorbidity index uses a dichotomous categorization of whether a certain comorbidity is present or absent, the index has been validated to have predictive values for healthcare consumption, hospitalization, and even mortality risk (Elixhauser et al., 1998). Therefore, our study identifies a mood disorder association with comorbid medical conditions such as peptic ulcers, weight loss, and cardiovascular/circulatory diseases. The observed mood disorders' associations with acute and chronic medical conditions are compelling. They could contribute to improving diagnostic practices currently designed to fractionate mood/mental disorders from co-occurring conditions and provide a framework for predicting morbidity and mortality outcomes. Our results add to the current evidence highlighting the need to reduce the stigma associated with mood disorders and encourage a paradigm shift towards considering the possible clinical and physiological heterogeneity of mood disorders and other medical conditions at various mechanistic and etiological levels. In sum, using a large population-based

investigation, our results highlight the importance of understanding prevalent comorbidities between mood disorders and other acute and chronic medical conditions.

## REFERENCES

2018. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 392, 1789-1858.

Arasappan, D., Eickhoff, S.B., Nemeroff, C.B., Hofmann, H.A., Jabbi, M., 2021. Transcription Factor Motifs Associated with Anterior Insula Gene Expression Underlying Mood Disorder Phenotypes. *Mol Neurobiol* 58, 1978-1989.

Baltrusch H.J., Stangel W., Titze I., 1991. Stress, cancer and immunity. New developments in biopsychosocial and psychoneuroimmunologic research. *Acta Neurol (Napoli)*, 13, 315-27.

Brewerton T.D., 2022. Mechanisms by which adverse childhood experiences, other traumas and PTSD influence the health and well-being of individuals with eating disorders throughout the life span. *J Eat Disord*, 10(1), 162.

Collins, P.Y., Patel, V., Joestl, S.S., March, D., Insel, T.R., Daar, A.S., Bordin, I.A., Costello, E.J., Durkin, M., Fairburn, C., Glass, R.I., Hall, W., Huang, Y., Hyman, S.E., Jamison, K., Kaaya, S., Kapur, S., Kleinman, A., Ogunniyi, A., Otero-Ojeda, A. et al, 2011. Grand challenges in global mental health. *Nature* 475, 27-30.

Dalby M, Vitezic M, Plath N, Hammer-Helmich L, Jiang Y, Tian C, Dhamija D, Wilson CH, Hinds D; 23andMe Research Team; Sullivan PF, Buckholtz JW, Smoller JW., 2022. Characterizing mood disorders

in the AFFECT study: a large, longitudinal, and phenotypically rich genetic cohort in the US. *Transl Psychiatry*, 25;12(1):121.

Devanand, D.P., Lee, S., Huey, E.D., Goldberg, T.E., 2022. Associations Between Neuropsychiatric Symptoms and Neuropathological Diagnoses of Alzheimer Disease and Related Dementias. *JAMA Psychiatry* 79, 359-367.

Elixhauser, A., Steiner, C., Harris, D.R., Coffey, R.M., 1998. Comorbidity measures for use with administrative data. *Med Care* 36, 8-27.

Evans, D.L., Charney, D.S., Lewis, L., Golden, R.N., Gorman, J.M., Krishnan, K.R., Nemeroff, C.B., Bremner, J.D., Carney, R.M., Coyne, J.C., Delong, M.R., Frasure-Smith, N., Glassman, A.H., Gold, P.W., Grant, I., Gwyther, L., Ironson, G., Johnson, R.L., Kanner, A.M., Katon, W.J., et al., 2013. Burden of Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of Disease Study 2010. *PLOS Medicine* 10, e1001547.

Frasure-Smith, N., Lespérance, F., Talajic, M., 1995. Depression and 18-month prognosis after myocardial infarction. *Circulation* 91, 999-1005.

Garvey C, Criner G.J., 2018. Impact of Comorbidities on the Treatment of Chronic Obstructive Pulmonary Disease. *Am J Med* 131, (9S):23-29.

Greene, R.D., Cook, A., Nowaskie, D., Wang, S., 2020. Neurological Changes and Depression: 2020 Update. *Clin Geriatr Med* 36, 297-313.

Headrick, J.P., Peart, J.N., Budiono, B.P., Shum, D.H.K., Neumann, D.L., Stapelberg, N.J.C., 2017. The heartbreak of depression: 'Psycho-cardiac' coupling in myocardial infarction. *J Mol Cell Cardiol* 106, 14-28.

Insel, T.R., Charney, D.S., 2003. Research on Major Depression Strategies and Priorities. *JAMA* 289, 3167-3168.

Jabbi, M., Arasappan, D., Eickhoff, S.B., Strakowski, S.M., Nemeroff, C.B., Hofmann, H.A., 2020. Neuro-transcriptomic signatures for mood disorder morbidity and suicide mortality. *J Psychiatr Res* 127, 62-74.

Jabbi, M., Nemeroff, C.B., 2019. Convergent neurobiological predictors of mood and anxiety symptoms and treatment response. *Expert Rev Neurother* 19, 587-597.

Jackson NA, Jabbi M., 2022. Integrating biobehavioral information to predict mood disorder suicide risk. *Brain Behav Immun Health*, 24, 100495.

Jones, M., Corcoran, A., Jorge, R.E., 2019. The psychopharmacology of brain vascular disease/poststroke depression. *Handb Clin Neurol* 165, 229-241.

Kanner, A.M., 2009. Psychiatric issues in epilepsy: the complex relation of mood, anxiety disorders, and epilepsy. *Epilepsy Behav* 15, 83-87.

Kessler, R.C., Amminger, G.P., Aguilar-Gaxiola, S., Alonso, J., Lee, S., Ustün, T.B., 2007. Age of onset of mental disorders: a review of recent literature. *Curr Opin Psychiatry* 20, 359-364.



Kessler, R.C., Heeringa, S., Lakoma, M.D., Petukhova, M., Rupp, A.E., Schoenbaum, M., Wang, P.S., Zaslavsky, A.M., 2008. Individual and societal effects of mental disorders on earnings in the United States: results from the national comorbidity survey replication. *Am J Psychiatry* 165, 703-711.

Kim, C.-Y., Sivasundaram, L., LaBelle, M.W., Trivedi, N.N., Liu, R.W., Gillespie, R.J., 2018. Predicting adverse events, length of stay, and discharge disposition following shoulder arthroplasty: a comparison of the Elixhauser Comorbidity Measure and Charlson Comorbidity Index. *Journal of Shoulder and Elbow Surgery* 27, 1748-1755.

Machado, M.O., Veronese, N., Sanches, M., Stubbs, B., Koyanagi, A., Thompson, T., Tzoulaki, I., Solmi, M., Vancampfort, D., Schuch, F.B., Maes, M., Fava, G.A., Ioannidis, J.P.A., Carvalho, A.F., 2018. The association of depression and all-cause and cause-specific mortality: an umbrella review of systematic reviews and meta-analyses. *BMC Med* 16, 112.

Manning, J.S., 2005. Burden of illness in bipolar depression. *Prim Care Companion J Clin Psychiatry* 7, 259-267.

McGuire, T., Wells, K.B., Bruce, M.L., Miranda, J., Scheffler, R., Durham, M., Ford, D.E., Lewis, L., 2002. Burden of illness. *Ment Health Serv Res* 4, 179-185.

McIntyre, R.S., Berk, M., Brietzke, E., Goldstein, B.I., López-Jaramillo, C., Kessing, L.V., Malhi, G.S., Nierenberg, A.A., Rosenblat, J.D., Majeed, A., Vieta, E., Vinberg, M., Young, A.H., Mansur, R.B., 2020. Bipolar disorders. *Lancet* 396, 1841-1856.

Mendlewicz, J., 2009. Sleep disturbances: core symptoms of major depressive disorder rather than associated or comorbid disorders. *World J Biol Psychiatry* 10, 269-275.

Menendez, M.E., Ring, D., Harris, M.B., Cha, T.D., 2015. Predicting In-Hospital Mortality in Elderly Patients With Cervical Spine Fractures: A Comparison of the Charlson and Elixhauser Comorbidity Measures. *Spine (Phila Pa 1976)* 40, 809-815.

Momen, N.C., Plana-Ripoll, O., Agerbo, E., Benros, M.E., Børghlum, A.D., Christensen, M.K., Dalsgaard, S., Degenhardt, L., de Jonge, P., Debost, J.-C.P.G., Fenger-Grøn, M., Gunn, J.M., Iburg, K.M., Kessing, L.V., Kessler, R.C., Laursen, T.M., Lim, C.C.W., Mors, O., Mortensen, P.B., Musliner, K.L., et al., 2020. Association between Mental Disorders and Subsequent Medical Conditions. *New England Journal of Medicine* 382, 1721-1731.

Momen, N.C., Plana-Ripoll, O., Agerbo, E., Christensen, M.K., Iburg, K.M., Laursen, T.M., Mortensen, P.B., Pedersen, C.B., Prior, A., Weye, N., McGrath, J.J., 2022. Mortality Associated With Mental Disorders and Comorbid General Medical Conditions. *JAMA Psychiatry* 1, 79(5): 444-453.

Murray, C.J., Vos, T., Lozano, R., Naghavi, M., Flaxman, A.D., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J.A., Abdalla, S., Aboyans, V., Abraham, J., Ackerman, I., Aggarwal, R., Ahn, S.Y., Ali, M.K., Alvarado, M., Anderson, H.R., Anderson, L.M., Andrews, K.G., et al., 2012. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 380, 2197-2223.

Nikiphorou E, Lempp H, Kohrt B.A., 2019. Treatment failure in inflammatory arthritis: time to think about syndemics? *Rheumatology (Oxford)*, 58(9), 1526-1533.

Ormel, J., Von Korff, M., Burger, H., Scott, K., Demyttenaere, K., Huang, Y.Q., Posada-Villa, J., Pierre Lepine, J., Angermeyer, M.C., Levinson, D., de Girolamo, G., Kawakami, N., Karam, E., Medina-Mora, M.E., Gureje, O., Williams, D., Haro, J.M., Bromet, E.J., Alonso, J., Kessler, R., 2007. Mental disorders

among persons with heart disease - results from World Mental Health surveys. *Gen Hosp Psychiatry* 29, 325-334.

Otte, C., Gold, S.M., Penninx, B.W., Pariante, C.M., Etkin, A., Fava, M., Mohr, D.C., Schatzberg, A.F., 2016. Major depressive disorder. *Nature Reviews Disease Primers* 2, 16065.

Panagioti M, Scott C, Blakemore A, Coventry P.A., 2014. Overview of the prevalence, impact, and management of depression and anxiety in chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Disorder* 9, 1289-306.

Plana-Ripoll, O., Pedersen, C.B., Holtz, Y., Benros, M.E., Dalsgaard, S., de Jonge, P., Fan, C.C., Degenhardt, L., Ganna, A., Greve, A.N., Gunn, J., Iburg, K.M., Kessing, L.V., Lee, B.K., Lim, C.C.W., Mors, O., Nordentoft, M., Prior, A., Roest, A.M., Saha, S., et al. 2019. Exploring Comorbidity Within Mental Disorders Among a Danish National Population. *JAMA Psychiatry* 76, 259-270.

Read JR, Sharpe L, Modini M, Dear B.F., 2017. Multimorbidity and depression: A systematic review and meta-analysis. *J Affect Disorder* 221, 36-46.

Dattani S., Rodés-Guirao L., Ritchie H., Roser M., 2023. Mental Health. *OurWorldInData.org*: <https://ourworldindata.org/mental-health>

Struble, L.M., Sullivan, B.J., Hartman, L.S., 2014. Psychiatric disorders impacting critical illness. *Crit Care Nurs Clin North Am* 26, 115-138.

Stuller K.A., Jarrett B, DeVries A.C., Stress and social isolation increase vulnerability to stroke. *Exp Neurol*, 233, (1), 33-9.

Tylee, D.S., Lee, Y.K., Wendt, F.R., Pathak, G.A., Levey, D.F., De Angelis, F., Gelernter, J., Polimanti, R., 2022. An Atlas of Genetic Correlations and Genetically Informed Associations Linking Psychiatric and Immune-Related Phenotypes. *JAMA Psychiatry*.

Vaccarino, V., Almuwaqqat, Z., Kim, J.H., Hammadah, M., Shah, A.J., Ko, Y.A., Elon, L., Sullivan, S., Shah, A., Alkholder, A., Lima, B.B., Pearce, B., Ward, L., Kutner, M., Hu, Y., Lewis, T.T., Garcia, E.V., Nye, J., Sheps, D.S., Raggi, P., Bremner, J.D., Quyyumi, A.A., 2021. Association of Mental Stress-Induced Myocardial Ischemia With Cardiovascular Events in Patients With Coronary Heart Disease. *Jama* 326, 1818-1828.

van Walraven, C., Austin, P.C., Jennings, A., Quan, H., Forster, A.J., 2009. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. *Med Care* 47, 626-633.

von Känel R., 2012. Psychosocial stress and cardiovascular risk: current opinion. *Swiss Med Wkly*, 142, w13502.

Weye, N., Momen, N.C., Christensen, M.K., Iburg, K.M., Dalsgaard, S., Laursen, T.M., Mortensen, P.B., Santomauro, D.F., Scott, J.G., Whiteford, H.A., McGrath, J.J., Plana-Ripoll, O., 2020. Association of Specific Mental Disorders With Premature Mortality in the Danish Population Using Alternative Measurement Methods. *JAMA Network Open* 3, e206646-e206646.

Whiteford, H.A., Ferrari, A.J., Vos, T., 2016. Challenges to estimating the true global burden of mental disorders. *The Lancet Psychiatry* 3, 402-403.

**Table 1: Demographic characteristics**

	<b>Non-mood disorder</b>	<b>Bipolar disorder</b>	<b>MDD</b>	<b>Mood disorder</b>
N (%)	6,460,378	40,616 (0.61)	208,274 (3.10)	248,890 (3.71)
Age (mean, SD)	43.54 (12.46)	45.54 (12.42)	45.73 (12.64)	45.70 (12.61)
Age				
21-30 years	1,254,515 (19.42)	6,384 (15.72)	33,175 (15.93)	39,559 (15.89)
31-40 years	1,494,741 (23.14)	7,747 (19.07)	39,927 (19.17)	47,574 (19.15)
41-50 years	1,494,846 (23.14)	9,615 (23.67)	46,528 (22.34)	56,143 (22.56)
51-64 years	2,216,266 (34.31)	16,870 (41.54)	88,644 (42.56)	105,514 (42.39)
Sex				
Male	3,371,768 (52.19)	13,275 (32.68)	64,156 (30.80)	77,431 (31.11)
Female	3,088,600 (47.81)	27,341 (67.32)	144,118 (69.20)	171,495 (68.89)
Race/ethnicity				
Asian	399,277 (6.18)	763 (1.88)	44,10 (2.12)	5,173 (2.08)
African ancestry	640,576 (9.92)	4,084 (10.06)	17,656 (8.48)	21,740 (8.73)
Hispanic	901,773 (13.96)	3,535 (8.70)	20,556 (9.87)	24,091 (9.68)
Caucasian	4,145,930 (64.17)	30,193 (74.34)	155,327 (7.45)	185,520 (74.54)
Missing	372,821 (5.77)	2,041 (5.03)	103,25 (4.95)	12,364 (4.97)

MDD: Major Depressive Disorder

SD: Standard Deviation

**Table 2: Descriptive statistics of chronic comorbid conditions by outcome variable**

<b>Comorbidities N (%)</b>	<b>Overall</b>	<b>Bipolar disorder</b>	<b>MDD</b>	<b>Mood disorder</b>
Blood loss anemia	27,608 (0.41)	353 (0.87)	2,014 (0.97)	3,350 (8.25)
Cardiac arrhythmia	250,284 (3.73)	3,350 (8.25)	16,276 (7.81)	8,680 (21.37)
Chronic pulmonary disease	484,488 (7.22)	8,680 (21.37)	35,856 (17.21)	729 (1.79)
coagulopathy	58,211 (0.87)	729 (1.79)	4,044 (1.94)	1,202 (2.96)
Congestive heart failure	80,309 (1.20)	1,202 (2.96)	6,284 (3.02)	2,082 (5.13)
Deficiency anemia	139,970 (2.08)	2,082 (5.13)	10,395 (4.99)	4,464 (10.99)
Diabetes complicated	297,484 (4.43)	4,464 (10.99)	21,498 (10.32)	6,244 (15.37)
Diabetes uncomplicated	449,183 (6.69)	6,244 (15.37)	27,807 (13.35)	3,061 (7.53)
Fluid conditions	162,110 (2.42)	3,061 (7.54)	13,093 (6.29)	264 (0.65)
HIV/AIDS	18,278 (0.27)	264 (0.65)	1,211 (0.58)	14,225 (35.02)
Hypertension	1,299,884 (19.37)	14,225 (35.02)	71,537 (34.35)	7,743 (19.06)
Hypothyroidism	477,842 (7.12)	7,743 (19.06)	32,120 (15.42)	2,240 (5.51)
Liver disease	146,492 (2.18)	2,240 (5.51)	10,003 (4.80)	95 (0.23)
Lymphoma	11,459 (0.17)	95 (0.23)	614 (0.29)	167 (0.41)
Metastatic cancer	23,685 (0.35)	167 (0.41)	1,362 (0.65)	9,903 (24.38)
Obesity	712,964 (10.63)	9,903 (24.38)	50,389 (24.19)	354 (0.87)
Peptic ulcers	19,112 (0.28)	354 (0.87)	1,694 (0.81)	1,423 (3.50)
Peripheral vascular disorder	87,651 (1.31)	1,423 (3.50)	7,826 (3.76)	497 (1.22)
Pulmonary circulation disorder	30,310 (0.45)	497 (1.22)	2,708 (1.30)	2,309 (5.68)
Rheumatoid Arthritis	135,834 (2.02)	2,309 (5.68)	11,526 (5.53)	1,999 (4.92)
Renal failure	99,955 (1.49)	1,999 (4.92)	8,439 (4.05)	1,141 (2.81)
Tumor without metastasis	134,320 (2.00)	1,141 (2.81)	7,326 (3.52)	1,278 (3.14)
Valvular disease	113,328 (1.69)	1,278 (3.15)	6,739 (3.23)	1,095 (2.70)

Weight loss	51,730 (0.77)	1,095 (2.69)	4,896 (2.35)	13,592 (33.46)
No comorbidities	4,210,233 (62.75)	13,592 (33.46)	74,868 (35.95)	8,957 (22.05)
1 comorbid condition	1,193,517 (17.79)	8,957 (22.05)	49,092 (23.57)	18,067 (44.48)
2 or more comorbid conditions	1,305,508 (19.46)	18,067 (44.48)	84,314 (40.48)	3,350 (8.24)
MDD: Major Depressive Disorder				

**Table 3: Adjusted Odds Ratio**

Co-variates		OR	Confidence Interval	
<b>Bipolar Disorder</b>				
Race				
	Asian	0.303	0.282	0.326
	Black	0.804	0.778	0.831
	Hispanic	0.575	0.555	0.595
Age		1.003	1.002	1.004
Sex		2.056	2.013	2.101
Comorbidities				
	Weight loss	2.016	1.89	2.152
	Peptic ulcers	1.616	1.447	1.806
	Chronic pulmonary disease	2.700	2.632	2.770
	Fluid conditions	1.871	1.794	1.952
	Renal failure	2.091	1.987	2.199
Interaction term age*sex		2.052	2.008	2.097
<b>Major Depressive Disorder</b>				
Race				
	Asian	0.319	0.309	0.329
	Black	0.695	0.684	0.706
	Hispanic	0.631	0.621	0.640
Age		1.009	1.008	1.009
Sex		2.388	2.365	2.412
Comorbidities				
	Weight loss	2.460	2.384	2.54
	Peptic ulcers	2.054	1.948	2.166
	Pulmonary circulation disorder	1.912	1.832	1.995
	Peripheral vascular disease	2.444	2.382	2.507
	Rheumatoid arthritis	2.057	2.014	2.100
Interaction term age*sex		2.379	2.356	2.402
<b>Mood Disorder</b>				
Race				
	Asian	0.309	0.3	0.317
	Black	0.702	0.692	0.712
	Hispanic	0.612	0.604	0.621
Age		1.008	1.008	1.009
Sex		2.435	2.413	2.457
Comorbidities				
	Weight loss	2.533	2.461	2.608
	Peptic ulcers	2.106	2.005	2.212



Pulmonary circulation disorder	1.765	1.696	1.837
Peripheral vascular disease	2.239	2.185	2.294
Renal failure	2.36	2.306	2.414
Interaction term age*sex	2.42	2.398	2.442

Reference groups: Race = Caucasian; Sex = Males

All p values <0.0001

## Appendix 1: ICD-10 codes for exclusion criteria

Code	Description
G10.x	Huntington's chorea · Huntington's dementia.
G11.x	Hereditary ataxia.
G12.x	Spinal Muscular Atrophy and Related Syndromes
G13.x	Systemic atrophies primarily affecting the central nervous system in diseases classified elsewhere.
G20.x	Parkinson's disease.
G21.x	Secondary parkinsonism.
G22.x	Secondary parkinsonism, unspecified
G35.x	multiple sclerosis
G36.x	Other acute disseminated demyelination
G37.x	Other demyelinating diseases of the central nervous system.
G25.4	Drug-induced chorea
G25.5	Other chorea
G31.2	Degeneration of nervous system due to alcohol
G31.8	Other specified degenerative diseases of the nervous system
G31.9	Degenerative disease of the nervous system, unspecified
G93.1	Anoxic brain damage, not elsewhere classified.
G39.4	Other and unspecified encephalopathy.
R47.0	Dysphasia and aphasia
G32.x	Other degenerative disorders of the nervous system in diseases are classified elsewhere.
G40.x	Epilepsy and recurrent seizures
G41.x	Status epilepticus
R56.x	Convulsions, not elsewhere classified
G04.1	Tropical spastic paraplegia
G80.1	Spastic diplegic cerebral palsy
G80.2	Spastic hemiplegic cerebral palsy
G81.x	Hemiplegia and hemiparesis following unspecified cerebrovascular disease.
G82.x	Paraplegia (paraparesis) and quadriplegia (quadriparesis)
G83.0	Diplegia of upper limbs
G83.1	Monoplegia of lower limb
G83.2	Monoplegia of upper limb.
G83.4	Cauda equina syndrome

G83.9	Paralytic syndrome, unspecified
G32.x	Other degenerative disorders of nervous system in diseases classified elsewhere
G93.1	Anoxic brain damage, not elsewhere classified
G93.4	Other and unspecified encephalopathy
R47.0	Dysphasia and aphasia
F10.x	Alcohol related disorders
E52.x	Niacin deficiency [pellagra]
G62.1	Alcoholic polyneuropathy
I42.6	Alcoholic cardiomyopathy
K29.2	Alcoholic gastritis
K70.0	Alcoholic fatty liver
K70.3	Alcoholic cirrhosis of liver
K70.9	Alcoholic liver disease, unspecified
T51.x	Toxic effect of alcohol
Z50.2	Alcohol rehabilitation
Z71.4	Alcohol abuse counseling and surveillance
Z72.1	Alcohol use
F20.x	Schizophrenia.
F22.x	Delusional Disorders
F23.x	Brief psychotic disorder
F24.x	Shared psychotic disorder
F25.x	Schizoaffective disorder, bipolar disorder type
F28.x	Other psychotic disorder not due to a substance or known physiological condition
F29.x	Unspecified psychosis not due to a substance or known physiological condition
F30.2	Mania with psychotic symptoms
F11.x	Opioid related disorders.
F12.x	Cannabis abuse, uncomplicated
F13.x	Sedative, hypnotic or anxiolytic abuse, uncomplicated
F14.x	use of cocaine
F15.x	use of other stimulants, including caffeine
F16.x	use of hallucinogens
F18.x	use of inhalants
F19.x	use of other psychoactive substances and multiple drug use
Z71.5	Drug abuse counseling and surveillance.
Z72.2	Drug use

---

## Appendix 2: ICD-10 codes identifying mood disorder

Code	Description
<b>Bipolar Disorder</b>	
F3110	Bipolar disorder, current episode manic without psychotic features, unspecified
F3111	Bipolar disorder, current episode manic without psychotic features, mild.
F3112	Bipolar disorder, current episode manic without psychotic features, moderate
F3113	Bipolar disorder, current episode manic without psychotic features, severe
F312	Bipolar affective disorder, current episode manic with psychotic symptoms
F3130	Bipolar disorder, current episode depressed, mild or moderate severity, unspecified.
F3131	Bipolar disorder, current episode depressed, mild.
F314	Bipolar affective disorder, current episode severe depression without psychotic symptoms.
F315	Bipolar disorder, current episode depressed, severe, with psychotic features
F3160	Bipolar disorder, current episode mixed, unspecified
F3161	Bipolar disorder, current episode mixed, mild.
F3162	Bipolar disorder, current episode mixed, moderate
F3163	Bipolar disorder, current episode mixed, severe, without psychotic features.
F3164	Bipolar disorder, current episode mixed, severe, with psychotic features.
F3170	Bipolar disorder, currently in remission, most recent episode unspecified.
F3171	Bipolar disorder, in partial remission, most recent episode hypomanic.
F3172	Bipolar disorder, in full remission, most recent episode hypomanic
F3173	Bipolar disorder, in partial remission, most recent episode manic.
F3174	Bipolar disorder, in full remission, most recent episode manic.
F3175	Bipolar disorder, in partial remission, most recent episode depressed
F3176	Bipolar disorder, in full remission, most recent episode depressed.
F3177	Bipolar disorder, in partial remission, most recent episode mixed
F3178	Bipolar disorder, in full remission, most recent episode mixed.
F3181	Bipolar II disorder.
F3132	Bipolar disorder, current episode depressed, moderate.
<b>Major Depressive Disorder</b>	
F330	Major depressive disorder, recurrent, mild
F331	Major depressive disorder, recurrent, moderate.
F332	Recurrent depressive disorder, current episode severe without psychotic symptoms. A
F333	Recurrent depressive disorder, current episode severe with psychotic symptoms.
F312	Bipolar affective disorder, current episode manic with psychotic symptoms.
F3340	Major depressive disorder, recurrent, in remission, unspecified
F3341	Major depressive disorder, recurrent, in partial remission.
F3342	Major depressive disorder, recurrent, in full remission.
F338	Other recurrent depressive disorders.
F339	Major depressive disorder, recurrent, unspecified.